Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of <4.0)

被引：0
|
作者：
Hoda, Raza [1 ]
McIntire, Patrick [1 ]
Komforti, Miglena [1 ]
Downs-Kelly, Erinn [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
LABORATORY INVESTIGATION | 2021年 / 101卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
100
引用
收藏
页码：111 / 113
页数：3
相关论文
共 50 条
  • [41] Relationship between Pathological Features, Her2 Protein Expression, and HER2 and CEP17 Copy Numbers in DCIS.
    Lambein, K.
    Van Bockstal, M.
    Praet, M.
    Denys, H.
    Braems, G.
    Nuyts, A.
    Cocquyt, V.
    Pauweis, P.
    Van Den Broecke, R.
    Libbrecht, L.
    CANCER RESEARCH, 2011, 71
  • [42] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
  • [43] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    MODERN PATHOLOGY, 2019, 32
  • [44] Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multiinstitutional Cohort Analysis Emphasizing Outcome and Molecular Subtype
    Ajabnoor, Rana
    Zhang, Gloria
    Hu, Yan
    Gao, Yuan
    Finkelman, Brian S.
    Turner, Bradley M.
    Yi, Sha
    Dhakal, Ajay
    Audeh, William
    Li, Zaibo
    Li, Xiaoxian
    Hicks, David G.
    Zhang, Huina
    MODERN PATHOLOGY, 2024, 37 (08)
  • [45] Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes
    Ballard, Morgan
    Troxell, Megan
    Jensen, Kristin
    Allison, Kimberly H.
    MODERN PATHOLOGY, 2017, 30 : 31A - 31A
  • [46] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis
    Mohamed, Nada
    Asirvatham, Jaya
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 165 - 166
  • [47] Pathological and Clinical Features Associated with Invasive Breast Cancer ISH Group 3 Classified According to the 2018 CAP/ASCO HER2 Guidelines: A Retrospective Analysis
    Mohamed, Nada
    Asirvatham, Jaya
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 165 - 166
  • [48] Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes
    Ballard, Morgan
    Troxell, Megan
    Jensen, Kristin
    Allison, Kimberly H.
    LABORATORY INVESTIGATION, 2017, 97 : 31A - 31A
  • [49] HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe, Marian Priyanthi
    de Boer, Willem Bastiaan
    Khor, Tze Sheng
    Ooi, Esther M.
    Jene, Nic
    Jayasinghe, Sureshini
    Fox, Stephen B.
    PATHOLOGY, 2014, 46 (03) : 184 - 187
  • [50] The prognostic importance of high HER2 copy numbers and high HER2/CEP17 ratio in trastuzumab-treated early breast cancer
    Ronnlund, C.
    Robertson, S.
    Sifakis, E. G.
    Fredriksson, I.
    Foukakis, T.
    Hartman, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S614 - S614
12345